APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Disease Aerosol Delivery Devices

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pulmonary Disease Aerosol Delivery Devices Market Outlook and Growth Opportunities 2026

Report ID 174029940429 December 2025192 pages

Choose your research edition.

Industry ResearchPulmonary Disease Aerosol Delivery Devices Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Disease Aerosol Delivery Devices Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Pulmonary Disease Aerosol Delivery Devices Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Disease Aerosol Delivery Devices Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Disease Aerosol Delivery Devices Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Pulmonary Disease Aerosol Delivery Devices market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pulmonary Disease Aerosol Delivery Devices is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pulmonary Disease Aerosol Delivery Devices is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Disease Aerosol Delivery Devices is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pulmonary Disease Aerosol Delivery Devices market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pulmonary Disease Aerosol Delivery Devices market include Novartis, Merck, Viatris, GlaxoSmithKline (GSK), AstraZeneca, Vectura, Teva Pharmaceutical Industries, PARI International and OMRON, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pulmonary Disease Aerosol Delivery Devices market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pulmonary Disease Aerosol Delivery Devices and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pulmonary Disease Aerosol Delivery Devices sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pulmonary Disease Aerosol Delivery Devices market size, projected growth trends, production technologies, key applications, and end-use industries.

Pulmonary Disease Aerosol Delivery Devices Segment by Company

Novartis

Merck

Viatris

GlaxoSmithKline (GSK)

AstraZeneca

Vectura

Teva Pharmaceutical Industries

PARI International

OMRON

Monaghan Medical

Koninklijke Philips

H&T Presspart

Chiesi Farmaceutici

Boehringer Ingelheim

AptarGroup

Pulmonary Disease Aerosol Delivery Devices Segment by Type

Metered- dose Inhalers

Dry-powder Inhalers

Nebulizers

Pulmonary Disease Aerosol Delivery Devices Segment by Application

Asthma

Idiopathic Pulmonary Fibrosis (IPF)

Cystic Fibrosis (CF)

Chronic Obstructive Pulmonary Disease (COPD)

Others

Pulmonary Disease Aerosol Delivery Devices Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pulmonary Disease Aerosol Delivery Devices status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pulmonary Disease Aerosol Delivery Devices market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pulmonary Disease Aerosol Delivery Devices significant trends, drivers, influence factors in global and regions.

6. To analyze Pulmonary Disease Aerosol Delivery Devices competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Disease Aerosol Delivery Devices market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Disease Aerosol Delivery Devices and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Disease Aerosol Delivery Devices.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pulmonary Disease Aerosol Delivery Devices market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pulmonary Disease Aerosol Delivery Devices industry.

Chapter 3: Detailed analysis of Pulmonary Disease Aerosol Delivery Devices manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pulmonary Disease Aerosol Delivery Devices in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pulmonary Disease Aerosol Delivery Devices in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pulmonary Disease Aerosol Delivery Devices Industry Trends Table 2. Pulmonary Disease Aerosol Delivery Devices Industry Drivers Table 3. Pulmonary Disease Aerosol Delivery Devices Industry Opportunities and Challenges Table 4. Pulmonary Disease Aerosol Delivery Devices Industry Restraints Table 5. Global Pulmonary Disease Aerosol Delivery Devices Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pulmonary Disease Aerosol Delivery Devices Revenue Share by Company (2021-2026) Table 7. Global Pulmonary Disease Aerosol Delivery Devices Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Pulmonary Disease Aerosol Delivery Devices Sales Volume Share by Company (2021-2026) Table 9. Global Pulmonary Disease Aerosol Delivery Devices Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Pulmonary Disease Aerosol Delivery Devices Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pulmonary Disease Aerosol Delivery Devices Key Company Manufacturing Base & Headquarters Table 12. Global Pulmonary Disease Aerosol Delivery Devices Company, Product Type & Application Table 13. Global Pulmonary Disease Aerosol Delivery Devices Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pulmonary Disease Aerosol Delivery Devices by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Metered- dose Inhalers Table 18. Significant Companies of Dry-powder Inhalers Table 19. Significant Companies of Nebulizers Table 20. Global Pulmonary Disease Aerosol Delivery Devices Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Pulmonary Disease Aerosol Delivery Devices Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Pulmonary Disease Aerosol Delivery Devices Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Pulmonary Disease Aerosol Delivery Devices Sales Volume Share by Type (2021-2026) Table 24. Global Pulmonary Disease Aerosol Delivery Devices Sales Volume Share by Type (2027-2032) Table 25. Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type (2021-2026) Table 29. Global Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Asthma Table 31. Significant Companies of Idiopathic Pulmonary Fibrosis (IPF) Table 32. Significant Companies of Cystic Fibrosis (CF) Table 33. Significant Companies of Chronic Obstructive Pulmonary Disease (COPD) Table 34. Significant Companies of Others Table 35. Global Pulmonary Disease Aerosol Delivery Devices Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Pulmonary Disease Aerosol Delivery Devices Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Pulmonary Disease Aerosol Delivery Devices Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Pulmonary Disease Aerosol Delivery Devices Sales Volume Share by Application (2021-2026) Table 39. Global Pulmonary Disease Aerosol Delivery Devices Sales Volume Share by Application (2027-2032) Table 40. Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application (2021-2026) Table 44. Global Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application (2027-2032) Table 45. Global Pulmonary Disease Aerosol Delivery Devices Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Pulmonary Disease Aerosol Delivery Devices Sales by Region (2021-2026) & (K Units) Table 47. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Region (2021-2026) Table 48. Global Pulmonary Disease Aerosol Delivery Devices Sales by Region (2027-2032) & (K Units) Table 49. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Region (2027-2032) Table 50. Global Pulmonary Disease Aerosol Delivery Devices Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Region (2021-2026) Table 53. Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Region (2027-2032) Table 55. Global Pulmonary Disease Aerosol Delivery Devices Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Pulmonary Disease Aerosol Delivery Devices Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Pulmonary Disease Aerosol Delivery Devices Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2026) & (K Units) Table 60. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Country (2021-2026) Table 61. Global Pulmonary Disease Aerosol Delivery Devices Sales by Country (2027-2032) & (K Units) Table 62. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Country (2027-2032) Table 63. Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Pulmonary Disease Aerosol Delivery Devices Sales Value Market Share by Country (2021-2026) Table 65. Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Pulmonary Disease Aerosol Delivery Devices Sales Value Market Share by Country (2027-2032) Table 67. Novartis Company Information Table 68. Novartis Business Overview Table 69. Novartis Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Novartis Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 71. Novartis Recent Development Table 72. Merck Company Information Table 73. Merck Business Overview Table 74. Merck Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Merck Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 76. Merck Recent Development Table 77. Viatris Company Information Table 78. Viatris Business Overview Table 79. Viatris Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Viatris Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 81. Viatris Recent Development Table 82. GlaxoSmithKline (GSK) Company Information Table 83. GlaxoSmithKline (GSK) Business Overview Table 84. GlaxoSmithKline (GSK) Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. GlaxoSmithKline (GSK) Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 86. GlaxoSmithKline (GSK) Recent Development Table 87. AstraZeneca Company Information Table 88. AstraZeneca Business Overview Table 89. AstraZeneca Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. AstraZeneca Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 91. AstraZeneca Recent Development Table 92. Vectura Company Information Table 93. Vectura Business Overview Table 94. Vectura Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Vectura Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 96. Vectura Recent Development Table 97. Teva Pharmaceutical Industries Company Information Table 98. Teva Pharmaceutical Industries Business Overview Table 99. Teva Pharmaceutical Industries Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Teva Pharmaceutical Industries Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 101. Teva Pharmaceutical Industries Recent Development Table 102. PARI International Company Information Table 103. PARI International Business Overview Table 104. PARI International Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. PARI International Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 106. PARI International Recent Development Table 107. OMRON Company Information Table 108. OMRON Business Overview Table 109. OMRON Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. OMRON Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 111. OMRON Recent Development Table 112. Monaghan Medical Company Information Table 113. Monaghan Medical Business Overview Table 114. Monaghan Medical Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Monaghan Medical Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 116. Monaghan Medical Recent Development Table 117. Koninklijke Philips Company Information Table 118. Koninklijke Philips Business Overview Table 119. Koninklijke Philips Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Koninklijke Philips Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 121. Koninklijke Philips Recent Development Table 122. H&T Presspart Company Information Table 123. H&T Presspart Business Overview Table 124. H&T Presspart Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. H&T Presspart Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 126. H&T Presspart Recent Development Table 127. Chiesi Farmaceutici Company Information Table 128. Chiesi Farmaceutici Business Overview Table 129. Chiesi Farmaceutici Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Chiesi Farmaceutici Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 131. Chiesi Farmaceutici Recent Development Table 132. Boehringer Ingelheim Company Information Table 133. Boehringer Ingelheim Business Overview Table 134. Boehringer Ingelheim Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Boehringer Ingelheim Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 136. Boehringer Ingelheim Recent Development Table 137. AptarGroup Company Information Table 138. AptarGroup Business Overview Table 139. AptarGroup Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. AptarGroup Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 141. AptarGroup Recent Development Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Pulmonary Disease Aerosol Delivery Devices Distributors List Table 145. Pulmonary Disease Aerosol Delivery Devices Customers List Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. Pulmonary Disease Aerosol Delivery Devices Product Image Figure 2. Global Pulmonary Disease Aerosol Delivery Devices Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Disease Aerosol Delivery Devices Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pulmonary Disease Aerosol Delivery Devices Sales (2021-2032) & (K Units) Figure 5. Global Pulmonary Disease Aerosol Delivery Devices Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Pulmonary Disease Aerosol Delivery Devices Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Metered- dose Inhalers Image Figure 10. Dry-powder Inhalers Image Figure 11. Nebulizers Image Figure 12. Global Pulmonary Disease Aerosol Delivery Devices Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Pulmonary Disease Aerosol Delivery Devices Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Pulmonary Disease Aerosol Delivery Devices Sales Volume Share by Type (2021-2032) Figure 15. Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Pulmonary Disease Aerosol Delivery Devices Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type (2021-2032) Figure 18. Asthma Image Figure 19. Idiopathic Pulmonary Fibrosis (IPF) Image Figure 20. Cystic Fibrosis (CF) Image Figure 21. Chronic Obstructive Pulmonary Disease (COPD) Image Figure 22. Others Image Figure 23. Global Pulmonary Disease Aerosol Delivery Devices Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Pulmonary Disease Aerosol Delivery Devices Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Pulmonary Disease Aerosol Delivery Devices Sales Volume Share by Application (2021-2032) Figure 26. Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Pulmonary Disease Aerosol Delivery Devices Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application (2021-2032) Figure 29. Global Pulmonary Disease Aerosol Delivery Devices Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Pulmonary Disease Aerosol Delivery Devices Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Pulmonary Disease Aerosol Delivery Devices Sales Value (2021-2032) & (US$ Million) Figure 34. North America Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Pulmonary Disease Aerosol Delivery Devices Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Pulmonary Disease Aerosol Delivery Devices Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Pulmonary Disease Aerosol Delivery Devices Sales Value (2021-2032) & (US$ Million) Figure 40. South America Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Pulmonary Disease Aerosol Delivery Devices Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Pulmonary Disease Aerosol Delivery Devices Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Pulmonary Disease Aerosol Delivery Devices Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Metered- dose Inhalers
  • Dry-powder Inhalers
  • Nebulizers
Applications
  • Asthma
  • Idiopathic Pulmonary Fibrosis (IPF)
  • Cystic Fibrosis (CF)
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others
Companies covered
  • Novartis
  • Merck
  • Viatris
  • GlaxoSmithKline (GSK)
  • AstraZeneca
  • Vectura
  • Teva Pharmaceutical Industries
  • PARI International
  • OMRON
  • Monaghan Medical
  • Koninklijke Philips
  • H&T Presspart
  • Chiesi Farmaceutici
  • Boehringer Ingelheim
  • AptarGroup

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pulmonary Disease Aerosol Delivery Devices Sales Value (2021-2032)
  4. 1.2.2 Global Pulmonary Disease Aerosol Delivery Devices Sales Volume (2021-2032)
  5. 1.2.3 Global Pulmonary Disease Aerosol Delivery Devices Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pulmonary Disease Aerosol Delivery Devices Market Dynamics
  1. 2.1 Pulmonary Disease Aerosol Delivery Devices Industry Trends
  2. 2.2 Pulmonary Disease Aerosol Delivery Devices Industry Drivers
  3. 2.3 Pulmonary Disease Aerosol Delivery Devices Industry Opportunities and Challenges
  4. 2.4 Pulmonary Disease Aerosol Delivery Devices Industry Restraints
3 Pulmonary Disease Aerosol Delivery Devices Market by Company
  1. 3.1 Global Pulmonary Disease Aerosol Delivery Devices Company Revenue Ranking in 2025
  2. 3.2 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Company (2021-2026)
  3. 3.3 Global Pulmonary Disease Aerosol Delivery Devices Sales Volume by Company (2021-2026)
  4. 3.4 Global Pulmonary Disease Aerosol Delivery Devices Average Price by Company (2021-2026)
  5. 3.5 Global Pulmonary Disease Aerosol Delivery Devices Company Ranking (2024-2026)
  6. 3.6 Global Pulmonary Disease Aerosol Delivery Devices Company Manufacturing Base and Headquarters
  7. 3.7 Global Pulmonary Disease Aerosol Delivery Devices Company Product Type and Application
  8. 3.8 Global Pulmonary Disease Aerosol Delivery Devices Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pulmonary Disease Aerosol Delivery Devices Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pulmonary Disease Aerosol Delivery Devices Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pulmonary Disease Aerosol Delivery Devices Market by Type
  1. 4.1 Pulmonary Disease Aerosol Delivery Devices Type Introduction
  2. 4.1.1 Metered- dose Inhalers
  3. 4.1.2 Dry-powder Inhalers
  4. 4.1.3 Nebulizers
  5. 4.2 Global Pulmonary Disease Aerosol Delivery Devices Sales Volume by Type
  6. 4.2.1 Global Pulmonary Disease Aerosol Delivery Devices Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pulmonary Disease Aerosol Delivery Devices Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Pulmonary Disease Aerosol Delivery Devices Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Type
  10. 4.3.1 Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Type (2021-2032)
  12. 4.3.3 Global Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type (2021-2032)
5 Pulmonary Disease Aerosol Delivery Devices Market by Application
  1. 5.1 Pulmonary Disease Aerosol Delivery Devices Application Introduction
  2. 5.1.1 Asthma
  3. 5.1.2 Idiopathic Pulmonary Fibrosis (IPF)
  4. 5.1.3 Cystic Fibrosis (CF)
  5. 5.1.4 Chronic Obstructive Pulmonary Disease (COPD)
  6. 5.1.5 Others
  7. 5.2 Global Pulmonary Disease Aerosol Delivery Devices Sales Volume by Application
  8. 5.2.1 Global Pulmonary Disease Aerosol Delivery Devices Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Pulmonary Disease Aerosol Delivery Devices Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Pulmonary Disease Aerosol Delivery Devices Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Application
  12. 5.3.1 Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Application (2021-2032)
  14. 5.3.3 Global Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application (2021-2032)
6 Pulmonary Disease Aerosol Delivery Devices Regional Sales and Value Analysis
  1. 6.1 Global Pulmonary Disease Aerosol Delivery Devices Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pulmonary Disease Aerosol Delivery Devices Sales by Region (2021-2032)
  3. 6.2.1 Global Pulmonary Disease Aerosol Delivery Devices Sales by Region: 2021-2026
  4. 6.2.2 Global Pulmonary Disease Aerosol Delivery Devices Sales by Region (2027-2032)
  5. 6.3 Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Region (2027-2032)
  9. 6.5 Global Pulmonary Disease Aerosol Delivery Devices Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pulmonary Disease Aerosol Delivery Devices Sales Value (2021-2032)
  12. 6.6.2 North America Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pulmonary Disease Aerosol Delivery Devices Sales Value (2021-2032)
  15. 6.7.2 Europe Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pulmonary Disease Aerosol Delivery Devices Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pulmonary Disease Aerosol Delivery Devices Sales Value (2021-2032)
  21. 6.9.2 South America Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Country, 2025 VS 2032
7 Pulmonary Disease Aerosol Delivery Devices Country-level Sales and Value Analysis
  1. 7.1 Global Pulmonary Disease Aerosol Delivery Devices Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2032)
  4. 7.3.1 Global Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2026)
  5. 7.3.2 Global Pulmonary Disease Aerosol Delivery Devices Sales by Country (2027-2032)
  6. 7.4 Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pulmonary Disease Aerosol Delivery Devices Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pulmonary Disease Aerosol Delivery Devices Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pulmonary Disease Aerosol Delivery Devices Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Pulmonary Disease Aerosol Delivery Devices Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Pulmonary Disease Aerosol Delivery Devices Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Viatris
  14. 8.3.1 Viatris Company Information
  15. 8.3.2 Viatris Business Overview
  16. 8.3.3 Viatris Pulmonary Disease Aerosol Delivery Devices Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Viatris Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  18. 8.3.5 Viatris Recent Developments
  19. 8.4 GlaxoSmithKline (GSK)
  20. 8.4.1 GlaxoSmithKline (GSK) Company Information
  21. 8.4.2 GlaxoSmithKline (GSK) Business Overview
  22. 8.4.3 GlaxoSmithKline (GSK) Pulmonary Disease Aerosol Delivery Devices Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline (GSK) Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  24. 8.4.5 GlaxoSmithKline (GSK) Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Pulmonary Disease Aerosol Delivery Devices Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Vectura
  32. 8.6.1 Vectura Company Information
  33. 8.6.2 Vectura Business Overview
  34. 8.6.3 Vectura Pulmonary Disease Aerosol Delivery Devices Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Vectura Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  36. 8.6.5 Vectura Recent Developments
  37. 8.7 Teva Pharmaceutical Industries
  38. 8.7.1 Teva Pharmaceutical Industries Company Information
  39. 8.7.2 Teva Pharmaceutical Industries Business Overview
  40. 8.7.3 Teva Pharmaceutical Industries Pulmonary Disease Aerosol Delivery Devices Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Teva Pharmaceutical Industries Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  42. 8.7.5 Teva Pharmaceutical Industries Recent Developments
  43. 8.8 PARI International
  44. 8.8.1 PARI International Company Information
  45. 8.8.2 PARI International Business Overview
  46. 8.8.3 PARI International Pulmonary Disease Aerosol Delivery Devices Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 PARI International Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  48. 8.8.5 PARI International Recent Developments
  49. 8.9 OMRON
  50. 8.9.1 OMRON Company Information
  51. 8.9.2 OMRON Business Overview
  52. 8.9.3 OMRON Pulmonary Disease Aerosol Delivery Devices Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 OMRON Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  54. 8.9.5 OMRON Recent Developments
  55. 8.10 Monaghan Medical
  56. 8.10.1 Monaghan Medical Company Information
  57. 8.10.2 Monaghan Medical Business Overview
  58. 8.10.3 Monaghan Medical Pulmonary Disease Aerosol Delivery Devices Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Monaghan Medical Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  60. 8.10.5 Monaghan Medical Recent Developments
  61. 8.11 Koninklijke Philips
  62. 8.11.1 Koninklijke Philips Company Information
  63. 8.11.2 Koninklijke Philips Business Overview
  64. 8.11.3 Koninklijke Philips Pulmonary Disease Aerosol Delivery Devices Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Koninklijke Philips Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  66. 8.11.5 Koninklijke Philips Recent Developments
  67. 8.12 H&T Presspart
  68. 8.12.1 H&T Presspart Company Information
  69. 8.12.2 H&T Presspart Business Overview
  70. 8.12.3 H&T Presspart Pulmonary Disease Aerosol Delivery Devices Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 H&T Presspart Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  72. 8.12.5 H&T Presspart Recent Developments
  73. 8.13 Chiesi Farmaceutici
  74. 8.13.1 Chiesi Farmaceutici Company Information
  75. 8.13.2 Chiesi Farmaceutici Business Overview
  76. 8.13.3 Chiesi Farmaceutici Pulmonary Disease Aerosol Delivery Devices Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Chiesi Farmaceutici Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  78. 8.13.5 Chiesi Farmaceutici Recent Developments
  79. 8.14 Boehringer Ingelheim
  80. 8.14.1 Boehringer Ingelheim Company Information
  81. 8.14.2 Boehringer Ingelheim Business Overview
  82. 8.14.3 Boehringer Ingelheim Pulmonary Disease Aerosol Delivery Devices Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Boehringer Ingelheim Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  84. 8.14.5 Boehringer Ingelheim Recent Developments
  85. 8.15 AptarGroup
  86. 8.15.1 AptarGroup Company Information
  87. 8.15.2 AptarGroup Business Overview
  88. 8.15.3 AptarGroup Pulmonary Disease Aerosol Delivery Devices Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 AptarGroup Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  90. 8.15.5 AptarGroup Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pulmonary Disease Aerosol Delivery Devices Value Chain Analysis
  2. 9.1.1 Pulmonary Disease Aerosol Delivery Devices Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pulmonary Disease Aerosol Delivery Devices Sales Mode & Process
  6. 9.2 Pulmonary Disease Aerosol Delivery Devices Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pulmonary Disease Aerosol Delivery Devices Distributors
  9. 9.2.3 Pulmonary Disease Aerosol Delivery Devices Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst